Oppenheimer Asset Management Inc. Reduces Position in Medtronic PLC $MDT

Oppenheimer Asset Management Inc. cut its position in shares of Medtronic PLC (NYSE:MDT) by 4.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 519,311 shares of the medical technology company’s stock after selling 24,907 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Medtronic were worth $49,885,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in MDT. Barclays PLC boosted its stake in shares of Medtronic by 104.6% during the 3rd quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company’s stock worth $650,604,000 after purchasing an additional 3,492,192 shares during the period. Schroder Investment Management Group boosted its holdings in Medtronic by 78.3% during the 3rd quarter. Schroder Investment Management Group now owns 7,529,849 shares of the medical technology company’s stock valued at $717,143,000 after acquiring an additional 3,307,211 shares during the period. Guinness Asset Management LTD purchased a new position in Medtronic during the 3rd quarter valued at $275,556,000. Wellington Management Group LLP boosted its holdings in Medtronic by 35.3% during the 3rd quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company’s stock valued at $970,456,000 after acquiring an additional 2,658,981 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in Medtronic by 2,297.7% during the 4th quarter. SG Americas Securities LLC now owns 2,510,712 shares of the medical technology company’s stock valued at $241,179,000 after acquiring an additional 2,406,000 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: FDA clearance for a next?generation mitral valve expands Medtronic’s structural?heart portfolio and could boost procedure volumes and long?term revenue. Medtronic wins FDA nod for next-gen mitral valve
• Positive Sentiment: CE mark for the Stealth AXiS surgical robot platform supports earlier commercial rollout in Europe and strengthens Medtronic’s surgical robotics / navigation offering. This is a commercialization milestone that can accelerate adoption outside the U.S. Medtronic wins CE mark for Stealth AXiS surgical robot platform
• Positive Sentiment: Affera-related wins (FDA Breakthrough Device for Sphere?9 and CE activity) and Medtronic’s progress on its cardiac ablation platform signal potential expansion into more complex arrhythmia treatments — a sizeable high?margin market if commercialized broadly. Affera Breakthrough: FDA Nod For Sphere-9 Could Be A Game Changer For Medtronic (MDT)
• Positive Sentiment: Enrollment of the first patient in a post?approval study for the Altaviva tibial neuromodulation device supports ongoing evidence generation and reimbursement positioning for a therapy targeting chronic indications — helps defend adoption and payer coverage. Medtronic enrolls first patient in post-approval study of Altaviva tibial neuromod
• Positive Sentiment: Market research reports for wearables and continuous glucose monitoring (Australia, Saudi Arabia, Middle East/Africa) highlight long?term TAM expansion in remote monitoring and diabetes care — areas where Medtronic has product exposure. These macro tailwinds support growth prospects for MDT’s diabetes & connected devices businesses. Australia Wearable Medical Devices Market Trends and Forecasts Saudi Arabia Wearable Medical Devices Market Trends and Forecasts Middle East and Africa Continuous Glucose Monitoring Market Forecast
• Neutral Sentiment: Analysts’ opinions are mixed on MDT — some see valuation upside once execution stabilizes, others flag near?term headwinds. Mixed analyst coverage tends to increase volatility but doesn’t change fundamentals immediately. Analysts’ Opinions Are Mixed on These Healthcare Stocks
• Neutral Sentiment: Industry moves (e.g., Teleflex CEO appointment) and FDA Breakthrough designations for other companies (Orchestra BioMed) are sector context items — they can affect competitive dynamics but are not direct Medtronic news. Teleflex Appoints Jason Weidman as President and CEO FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
• Negative Sentiment: UBS and Jefferies have trimmed their views/price targets after changes in Medtronic’s diabetes unit and model updates — analyst downgrades can pressure the stock and signal investor concern on near?term execution or margins. UBS and Jefferies Lower Views on Medtronic (MDT) Amid Diabetes Unit Changes
• Negative Sentiment: Coverage noting MDT is trading near recent lows and headlines about steeper intraday/closing drops can amplify bearish sentiment and short?term selling pressure even if fundamentals show product progress. Medtronic Near Lows: S&P 500 Index Healthcare Story to Watch Medtronic (MDT) Falls More Steeply Than Broader Market

Wall Street Analysts Forecast Growth

A number of brokerages have commented on MDT. Wall Street Zen downgraded shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Saturday, April 11th. Weiss Ratings cut Medtronic from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, April 21st. JPMorgan Chase & Co. lowered their target price on Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. Daiwa Securities Group lowered their price target on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Finally, Argus lowered their price target on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Fifteen investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $107.80.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.26% of the company’s stock.

Medtronic Trading Up 2.1%

NYSE:MDT opened at $81.07 on Friday. The stock has a market capitalization of $104.09 billion, a price-to-earnings ratio of 22.58, a PEG ratio of 2.06 and a beta of 0.75. Medtronic PLC has a 52 week low of $78.91 and a 52 week high of $106.33. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The firm has a 50 day moving average of $88.44 and a 200 day moving average of $94.82.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. Medtronic’s revenue was up 5.8% compared to the same quarter last year. During the same period last year, the firm earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts anticipate that Medtronic PLC will post 5.57 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were paid a $0.71 dividend. The ex-dividend date was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.5%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).